Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...
MarketBeat on MSN17h
What Does the Future Hold for Eli Lilly?GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new ...
Bloomfield Hills internal medicine physician Amjad Rass was excited to reunite with family in Syria last month for the first ...
Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), ...
Orlando Health Orlando Regional Medical Center has debuted its redesigned emergency room downtown. The nonprofit health ...
Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback